Case Series: Cariprazine in Early-onset Schizophrenia

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2023 May 1

PMID 37124247

Authors

Elena Ivanova

Desislava Maslinkova

Nadia Polnareva

Vihra Milanova

Affiliations

Soon will be listed here.

Abstract

Introduction: Negative symptoms are part of the clinical manifestations of schizophrenia and their presence is associated with a poorer prognosis, significantly limited vocational opportunities, impaired quality of life and social functioning. In the clinical practice, treatment of negative symptoms in patients with schizophrenia, is a challenge. Cariprazine is a novel partial agonist of D3 and D2 receptors, and shows a high affinity for D3, with good tolerability, good response to schizophrenic symptoms and limited side effects. We present two cases of young patients with predominantly negative symptoms during treatment with an atypical antipsychotic, administered in a stable dose and therapeutic range, and for at least 4 weeks prior to the Cariprazine switch.

Methods: Two patients (men aged 21 and 22) with schizophrenia, exhibiting predominantly negative symptoms, are presented. Their diagnosis was based on, DSM-5 criteria (295.10).Patients were treated with Cariprazine at a daily dose of 4.5 mg. They were followed for a period of 18 months and assessed with Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF) and Clinical Global Impression-Severity (CGI-S), at the fourth week of initiation of treatment with Cariprazine, at 6 months, at 12 months and at 18 months. Their mean initial value was 75.5 on PANSS, 4.0 on CGI-S, and 52.5 on GAF. Both patients were treated with stable doses of atypical antipsychotic-Risperidone at a daily dose of 4,5 mg. Cross-titration to Cariprazine was initiated, from 1.5 mg daily dose up to 4,5 mg daily dose, during a period of 2 weeks.

Results: After 18 months of treatment with Cariprazine at a daily dose of 4.5 mg, the following results were reported: mean value was 57.5 on PANSS, 3.0 on CGI-S, and 74.5 on GAF. The overall PANSS mean score decreased by 23.8%, the CGI-S mean score improved by 25% and the mean GAF score increased by 29.5%. The positive PANSS subscale score decreased minimally, from 20 to 16, while for the negative subscale the improvement was 29.8%.Cariprazine was well tolerated by patients and no side effects were observed from it during therapy.

Discussion: After 18 months Cariprazine succeeded in improving negative symptoms, global functioning, and global clinical impression. In young schizophrenic patients with a predominance of negative symptoms, the cariprazine may be a successful alternative.

Citing Articles

Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential.

Koziej S, Kowalczyk E, Soroka E Med Sci Monit. 2024; 30:e945411.

PMID: 39300746 PMC: 11421304. DOI: 10.12659/MSM.945411.

References

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S . Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019; 29(9):971-985. DOI: 10.1016/j.euroneuro.2019.06.008. View

Vasiliu O . Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms. Front Psychiatry. 2021; 12:786171. PMC: 8645548. DOI: 10.3389/fpsyt.2021.786171. View

Schimmelmann B, Conus P, Cotton S, McGorry P, Lambert M . Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res. 2007; 95(1-3):1-8. DOI: 10.1016/j.schres.2007.06.004. View

Girgis R, Xu X, Gil R, Hackett E, Ojeil N, Lieberman J . Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [(11)C]-(+)-PHNO. Schizophr Res. 2015; 168(1-2):373-6. PMC: 4591174. DOI: 10.1016/j.schres.2015.06.027. View

De Deurwaerdere P . Cariprazine:New dopamine biased agonist for neuropsychiatric disorders. Drugs Today (Barc). 2016; 52(2):97-110. DOI: 10.1358/dot.2016.52.2.2461868. View

Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S . Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2014; 41(4):892-9. PMC: 4466178. DOI: 10.1093/schbul/sbu170. View

Pelizza L, Leuci E, Maestri D, Quattrone E, Azzali S, Paulillo G . Longitudinal persistence of negative symptoms in young individuals with first episode schizophrenia: a 24-month multi-modal program follow-up. Nord J Psychiatry. 2021; 76(7):530-538. DOI: 10.1080/08039488.2021.2015431. View

Kirkpatrick B, Buchanan R, Ross D, Carpenter Jr W . A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001; 58(2):165-71. DOI: 10.1001/archpsyc.58.2.165. View

Van Dael F, van Os J, de Graaf R, Have M, Krabbendam L, Myin-Germeys I . Can obsessions drive you mad? Longitudinal evidence that obsessive-compulsive symptoms worsen the outcome of early psychotic experiences. Acta Psychiatr Scand. 2010; 123(2):136-46. DOI: 10.1111/j.1600-0447.2010.01609.x. View

10.

Orsolini L, de Berardis D, Volpe U . Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020; 19(8):981-998. DOI: 10.1080/14740338.2020.1795126. View

11.

Marder S . The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006; 8(1):109-13. PMC: 3181758. View

12.

Kahn R, Fleischhacker W, Boter H, Davidson M, Vergouwe Y, Keet I . Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371(9618):1085-97. DOI: 10.1016/S0140-6736(08)60486-9. View

13.

Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A . Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018; 268(7):625-639. DOI: 10.1007/s00406-018-0869-3. View

14.

Kaneko K . Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning. Yonago Acta Med. 2018; 61(2):91-102. PMC: 6015796. View

15.

Grover S, Dua D, Chakrabarti S, Avasthi A . Obsessive Compulsive Symptoms/disorder in patients with schizophrenia: Prevalence, relationship with other symptom dimensions and impact on functioning. Psychiatry Res. 2017; 250:277-284. DOI: 10.1016/j.psychres.2017.01.067. View

16.

Andreasen N . Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982; 39(7):784-8. DOI: 10.1001/archpsyc.1982.04290070020005. View

17.

Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker W . Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol. 2012; 23(3):196-204. DOI: 10.1016/j.euroneuro.2012.04.019. View

18.

Marder S, Galderisi S . The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017; 16(1):14-24. PMC: 5269507. DOI: 10.1002/wps.20385. View

19.

Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M . Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 80(Pt C):168-176. DOI: 10.1016/j.pnpbp.2017.06.031. View

20.

Faragian S, Kurs R, Poyurovsky M . Insight into obsessive-compulsive symptoms and awareness of illness in adolescent schizophrenia patients with and without OCD. Child Psychiatry Hum Dev. 2007; 39(1):39-48. DOI: 10.1007/s10578-007-0069-2. View